JNJ · News · 20260804N

Leadership Transition

JOHNSON & JOHNSON · 2026-08-04 · Importance 31 · Surprise 42

Jennifer Taubert will retire as Johnson & Johnson’s Executive Vice President and Worldwide Chairman of Innovative Medicine on September 1, 2026. Tom Cavanaugh, currently Company Group Chairman for North America, Innovative Medicine, will succeed her and join the Executive Committee on that date. Taubert’s 21-year tenure included growing Innovative Medicine to more than $60 billion in annual revenue, making the transition strategically significant for the company’s largest business.

Key facts

• During her leadership Jennifer Taubert significantly grew the company's Innovative Medicine business to over $60 billion in annual revenue. source
• Jennifer Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine at Johnson & Johnson, is set to retire after a distinguished 21-year career. source
• Tom Cavanaugh will succeed Jennifer Taubert and will join the Johnson & Johnson Executive Committee on September 1, 2026. source
• Tom Cavanaugh is currently Company Group Chairman, North America, Innovative Medicine. source